Technology: enzymatic DNA production

neDNA™: accelerating gene therapy

At TAAV we produce neDNA™ Enzymatic DNA Production as an alternative to plasmid DNA for the manufacture of recombinant adeno-associated virus (AAV). This disruptive technology is creating a new industry standard for transfection-based AAV production.

The synthetic process we use leads to high yields shortening manufacturing timelines, facilitating quicker production of AAV and potentially increasing safety by virtually eliminating bacterial sequences that are present when using plasmid DNA.

More about neDNA™.

neDNA™ is designed to transform
and accelerate the traditional
gene therapy development timelines 

Gene therapies are expected to experiment significant advances in the upcoming years.

These breakthrough innovations are reshaping how we address previously untreatable diseases transforming people’s lives.

After many decades of work, the future of gene therapy is incredibly promising. And neDNA™, Enzymatic DNA Production, can be the first option for critical starting material for AAV production.

Let’s work together to make it real.

Designed to prioritize safety and accelerate timelines.

Our team of experts has breadth and depth of experience providing AAV therapeutic developers with our innovative enzymatic DNA to support their manufacturing of rAAV based therapies.  

We provide neDNA™, Enzymatic DNA Manufacturing, at three quality grades to support various phases from R&D to clinical development and GMP compliant. 

Do you want to know more about how we can help you? Contact our team.

Manufacturing process

Reproducir vídeo
1

The starting point in our neDNA™ manufacturing process is a precursor plasmid produce in our facility. 

2

That contains the unique neDNA™ elements for production and processing.   

3

The initial step is the denaturation of the neDNA™ precursor plasmid to obtain two single DNA strands.

4

Next, we add the polymerase that copies the template incorporating nucleotides 

5

Once long DNA concatemers have been generated, we add restriction enzymes to process backbone sequences.

6

Telomerase (TelN) covalently close both ends of the gene of interest producing the neDNA™ molecules.

7

Finally, we add exonucleases to digest all open-ended DNA, leaving the neDNA™ intact.

8

The purification process removes all impurities, leaving the final neDNA™ product.

9

We believe neDNA™ is a likely safer, more scalable, robust and faster way to manufacture AAV, and produces higher yield.

Advantages of neDNA™: an alternative to plasmids  

Enzymatic DNA Production ready to use at TAAV Biomanufacturing

Plasmids have several major bottlenecks in gene therapy production, and one specifically that we solve with neDNA™: Production of plasmids may result in their genetic instability, which makes them susceptible to changes in sequence, particularly when encoding complex viral vectors.  

Our neDNA™ approach intends to be safer producing higher and faster yields at lower costs than plasmid.

TAAV neDNA Enzymatic DNA Manufacturing Gene Therapy Likely Safer

LIKELY
SAFER

 

neDNA™ is produced enzymatically and eliminates bacterial sequences, thus preventing aberrant packaging of bacterial origins of replication and antibiotic resistance genes.

TAAV neDNA Enzymatic DNA Manufacturing Gene Therapy More Effective

HIGHER
YIELD

neDNA™ production obtains more copies per gram of your sequence of interest, enabling you to transfect what you need.

Also, the total amount of DNA needed for transfection is reduced.

Producing comparable rAAV yields.

TAAV neDNA Enzymatic DNA Manufacturing Gene Therapy Scalable


SCALABLE

neDNA™ is manufactured from milligram to multi-gram scale with an identical process, in the same facility – Production increases to match need.

TAAV neDNA Enzymatic DNA Manufacturing Gene Therapy Faster

FASTER TO
MANUFACTURE

neDNA™ is manufactured in days, rather than months, and PO to delivery will be less than 3 months in most cases.

TAAV neDNA Enzymatic DNA Manufacturing Gene Therapy Robust


ROBUST

Enables batch-to-batch consistency.

TAAV neDNA Enzymatic DNA Manufacturing Gene Therapy Likely Safer

LIKELY
SAFER

neDNA™ is produced enzymatically and eliminates bacterial sequences, thus preventing aberrant packaging of bacterial origins of replication and antibiotic resistance genes.

TAAV neDNA Enzymatic DNA Manufacturing Gene Therapy More Effective

MORE
EFFECTIVE

neDNA™ production obtains more copies per gram of your sequence of interest, enabling you to transfect what you need.

Also, the total amount of DNA needed for transfection is reduced.

Producing comparable rAAV yields.

TAAV neDNA Enzymatic DNA Manufacturing Gene Therapy Scalable


SCALABLE

neDNA™ is manufactured from milligram to multi-gram scale with an identical process, in the same facility – Production increases to match need.

TAAV neDNA Enzymatic DNA Manufacturing Gene Therapy Faster

FASTER TO
MANUFACTURE

neDNA™ is manufactured in days, rather than months, and PO to delivery will be less than 3 months in most cases.

TAAV neDNA Enzymatic DNA Manufacturing Gene Therapy Robust


ROBUST

Enables batch-to-batch consistency.

Happy Holidays 2023